Join | Login







A | Advocacy

Your voice can help change what comes next.

Advocacy can start with learning, sharing your experience, asking a question or speaking up about something that needs to change. CanPKU+ works with people affected by PKU and allied disorders, healthcare teams, researchers and decision-makers to improve diagnosis, treatment, access and lifelong care across Canada.
CanPKU+ advocacy
CanPKU+ engages in non-partisan public policy dialogue and development activities that support our purposes of relieving sickness, advancing education and advancing health. We work with families, clinicians, policymakers and system leaders to improve access, equity and outcomes. Our advocacy is evidence-informed and independent of sponsor influence.

Start where you are

You do not need to be an expert to be an advocate. Learn about the issues, find practical ways to make your voice heard and help others understand why change matters.
Learn
Understanding the issue is often the first step toward changing it. Explore advocacy news, learn how access works in Canada and hear conversations about issues affecting people with PKU and allied disorders.
Advocacy Articles & Updates
Follow CanPKU+ advocacy news, consultations, access updates, policy developments, awareness initiatives and opportunities for patient and caregiver input.
Browse Advocacy Articles & Updates →
Rare Awareness Radio
Listen to conversations about rare disease awareness, lived experience, advocacy and issues that matter to our community.
Listen to Rare Awareness Radio →
Understanding Access
Learn how treatment access works in Canada and why access can differ depending on the treatment, condition and province or territory.
Explore Access
Be Heard
You do not need to be a policy expert or travel to a government meeting to advocate. Your experience and your voice matter. We can help you communicate with decision-makers, respond when opportunities arise and take action from wherever you live.
Advocacy at Home
Find practical ways to connect with decision-makers, support change and participate in advocacy from your own community.
Explore Advocacy at Home →
Advocacy Toolkit
Use practical resources to help communicate clearly and confidently with elected representatives, government officials and other decision-makers.
Open the Advocacy Toolkit →
Raise Awareness

Lived experience helps people understand

Awareness helps turn rare conditions from something unfamiliar into something decision-makers, healthcare systems and communities can understand.
Numbers and evidence matter, but lived experience shows what policies and access decisions mean in everyday life. Sharing your experience can help others understand barriers, gaps in care and opportunities for better outcomes.
Photo coming soon
Our Advocacy Foundation

Five Principles. One Commitment.

The challenges may differ across PKU, HCU, MSUD, UCDs and other inherited metabolic disorders, but these five principles guide CanPKU+'s work toward equitable care, treatment and support.
01
Lifelong Conditions Require Lifelong Care
Early diagnosis, timely intervention, ongoing monitoring and specialized care are essential throughout life, including adolescence and adulthood.
02
The Burden of Treatment Extends Beyond Medical Outcomes
Dietary management, medication, monitoring and complex routines can affect mental health, education, employment, relationships and family life.
03
Significant Unmet Needs and Inequities Remain
Gaps in treatment effectiveness, availability, affordability, public coverage and specialized care create unequal opportunities across Canada.
04
Treatment Innovation Must Improve Everyday Life
New treatments should be assessed not only by clinical measures, but also by their effects on independence, flexibility, daily functioning and quality of life.
05
Equitable Public Access Benefits Individuals, Families and Society
Timely, publicly funded access to safe and effective treatments can improve health, ease the burden on patients and caregivers, and support fuller participation in community life.

What we advocate for

The specific issue may change, but our goal remains consistent: people affected by PKU and allied disorders should have equitable access to timely diagnosis, appropriate treatment and lifelong care.
Federal
Access pathways, reimbursement fairness, Canada's rare disease strategy, medical foods and formulas, disability policy and national health initiatives.
Provincial & Territorial
We advocate for equitable access to treatment, medical nutrition, specialized care and other supports across Canada's provinces and territories.
Our areas of focus
Treatment Access
Timely and equitable access to appropriate treatments and specialized care.
Medical Nutrition
Recognition, coverage and access to medically necessary formulas, medical foods and low-protein foods.
Newborn Screening
Timely, evidence-informed and equitable newborn screening across Canada.
Disability & Tax Policy
Fair recognition of the impact of inherited metabolic disorders and equitable access to disability-related supports.
Rare Disease Policy
Ensuring our communities are represented in broader rare disease policy and health-system decisions.
Join In

Want to help move an issue forward?

Advocacy is stronger when people with lived experience are part of the conversation. Whether an issue affects you directly or you simply want to help, there are opportunities to contribute your experience, knowledge and voice.
Contact Us to Get Involved Update My Advocacy Interests
Information on this page is provided for general education and advocacy support. It is not a substitute for medical or legal advice. For questions about individual treatment or care, please speak with your metabolic clinic or healthcare provider.
Back to top ↑
Below is a historical overview of CanPKU+ advocacy, public engagement, education initiatives, and policy participation efforts in support of individuals and families affected by PKU and allied disorders across Canada.
2026
  • Received a positive final reimbursement recommendation from Canada’s Drug Agency (CDA-AMC) for Loargys® (pegzilarginase), with the final guidance reflecting key issues raised by CanPKU+ during consultation, including recognition of stabilization as a meaningful treatment outcome, flexibility around temporary arginine fluctuations, and the importance of preserving mobility, communication and participation in daily life.  See our Impact Review.
  • Submitted feedback on the draft recommendation for Loargys Pegzilarginase. to CDA.
  • Submitted a patient input submission to Canada's Drug Agency (CDA) on behalf of the Canadian PKU community as part of the review of Sephience™ (sepiapterin). The submission incorporated findings from the national patient and caregiver survey conducted in late 2025, along with one-on-one interviews describing the lived experience of PKU and the impact of current treatment.
  • Submitted a separate patient input submission to Quebec's Institut national d'excellence en santé et en services sociaux (INESSS) as part of its evaluation of Sephience™, ensuring that the experiences of individuals and families affected by PKU were represented within Quebec's review process.
  • Continued the Advocacy in Action program, creating provincial working groups in QC and AB
  • Participated in national discussions related to medicine access, health-system policy, and drug shortages, including stakeholder engagement through the Best Medicines Coalition and related patient advocacy networks.
  • Contributed patient organization perspectives to the development of the pan-Canadian Pharmaceutical Alliance's 2026-2029 Strategic Plan, which outlines future priorities related to people, process, performance, and strategic relationships.
  • Supported broader rare disease advocacy initiatives, including efforts encouraging governments and healthcare decision-makers to recognize the realities faced by Canadians living with rare and inherited metabolic disorders.
  • Continued developing advocacy education resources and website content to help community members better understand Health Canada approval, health technology assessment, reimbursement negotiations, and provincial and territorial drug funding decisions.
2025
2024
  • Supported advocacy capacity-building through completion of formal advocacy training by team members.
  • Launch of the Canadian PKU Registry (May 2, 2024): Read announcement
2023
  • Published Kuvan Fact Sheet (January 2023): Open document
  • Contributed patient perspective to national discussions regarding PMPRB reforms: Read article
2020 - 2022
  • Submitted formal comments to federal consultations, including PMPRB Draft Guidelines (2020), emphasizing the importance of patient access to medicines for rare disorders.
  • Participated in parliamentary and committee-level discussions relating to rare disease medicine access: House of Commons Health Committee record
  • Shared educational resources regarding how Canadian laws and regulations are developed: Justice Canada infographic
2013 - 2019
  • Engaged in national medicine-policy discussions through coalition participation (Best Medicines Coalition), ensuring rare disorder patient perspectives were represented.
  • Supported public funding approvals of Kuvan in multiple provinces beginning in 2013.
  • Advanced awareness of national PKU treatment guidelines and equitable access considerations: Newswire article
  • Supported provincial funding decisions for low-protein medical foods and formulas in multiple jurisdictions (2012–2015).
Foundational Years (2003 - 2012)
  • Grassroots advocacy efforts in multiple provinces contributed to maintaining access to medical formulas and improving standards of care.
  • Patient submissions to Common Drug Review processes regarding Kuvan.
  • CanPKU formally organized in 2008 to provide a national voice for individuals and families affected by PKU.
  • Earlier community-led efforts in 2003 to preserve adult formula access in Ontario helped catalyze later national organization.